Chronic Kidney Disease Pathway Document Description Presented ...

More documents

Recommendations

Info

Summary Sheet This pathway is intended to provide information on the management of people with Chronic Kidney Disease (CKD) to reduce their risks and to identify, prevent or delay the progression of associated co-morbid vascular and metabolic conditions. It is also intended to identify people who are deemed to be at high risk of developing CKD, to promote active screening of these people and to reduce or eliminate individual risk factors to reduce their overall level of risk. This policy applies directly to all staff members employed by NHS Dudley and Dudley Community Services who are involved in the management of people with CKD and is recommended as good practice guidance for each of the independent contractor professions. National and local guidance, policies, reports and/or papers which this particular document should be read in conjunction with: Local Guidance: • Best practice Guidelines for Lifestyle Assessment • Cardiovascular Risk pathway • Hyperlipidaemia Guidelines • Dudley Guidelines for the Pharmacological Management of Hypertension National Guidance: NICE Guidelines for: • Management of Chronic Kidney Disease • Secondary Prevention of Myocardial Infarction • Management of Patients with Heart Failure • Management of Hypertension • Lipid Modification • Management of Obesity National Service Frameworks for: • Coronary Heart Disease • Renal Services Part II • Diabetes This document will be subject to formal review in October 2011 led by the Vascular Programmes Local Implementation Team. 2
Pathway for the Identification and Management of Chronic Kidney Disease In the Primary Care Setting Implementation date: October 2009 Review date: October 2011 Pathway overview 3
Page 1: Chronic Kidney Disease Pathway Docu
Page 5 and 6: Contents Introduction …………
Page 7 and 8: Introduction Chronic kidney disease
Page 9 and 10: CKD Pathway D I A G N O S I S Ensur
Page 11 and 12: Kidney function deteriorates natura
Page 13 and 14: Joint Speciality Committee - Royal
Page 15 and 16: Acute Renal Failure Acute Renal Fai
Page 17 and 18: Next Steps Any patient suspected to
Page 19 and 20: Return to overview CKD Stages CKD S
Page 21 and 22: Practice Action Plan Compiling a Ch
Page 23 and 24: Action Rationale Responsible Run a
Page 25 and 26: eGFR
Page 27 and 28: CKD Stages CKD Stage Description Re
Page 29 and 30: References Joint Speciality Committ
Page 31 and 32: Cardiovascular Risk All patients wi
Page 33 and 34: Hypertension Blood pressure should
Page 35 and 36: Further information on the pharmaco
Page 37 and 38: Irbesartan* Valsartan Losartan* *Sp
Page 39 and 40: • Diuretics • Lithium carbonate
Page 41 and 42: Recommendation: Therefore consider
Page 43 and 44: Lower levels of proteinuria should
Page 45 and 46: Glycaemic Control CKD and Diabetes
Page 47 and 48: References Audit Commission (2002)
Page 49 and 50: Influenza and Pneumococcal Vaccine
Page 51 and 52: Stage 3 Management at stage 3 shoul
Page 53 and 54:
If all other causes for the anaemia
Page 55 and 56:
Clinic inclusion criteria: Patients
Page 57 and 58:
Where vitamin D supplementation is
Page 59 and 60:
Stage 5 Patients identified at CKD
Page 61 and 62:
Information to include with referra
Page 63 and 64:
Appendix 1 The Dudley Group of Hosp
show all

Chronic Kidney Disease Pathway Document Description Presented ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?